Capital Planning Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Capital Planning Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-360	Closed	-$36K	–	129
2019 Q3	$36K	Buy	+360	New	+$37.7K	0.01%	136
2018 Q1	–	Sell	-27,709	Closed	-$2.96M	–	123
2017 Q4	$2.96M	Buy	27,709 +5,743	+26%	+$614K	1.04%	28
2017 Q3	$2.44M	Buy	21,966 +5,088	+30%	+$544K	0.96%	31
2017 Q2	$1.75M	Buy	16,878 +13,644	+422%	+$1.34M	0.77%	39
2017 Q1	$316K	Buy	3,234 +6	+0.2%	+$574	0.16%	93
2016 Q4	$286K	Buy	3,228 +219	+7%	+$19.9K	0.15%	82
2016 Q3	$290K	Buy	3,009 +147	+5%	+$14K	0.15%	83
2016 Q2	$246K	Sell	2,862 -750	-21%	-$67.3K	0.14%	87
2016 Q1	$314K	Sell	3,612 -3,906	-52%	-$349K	0.15%	81
2015 Q4	$848K	Buy	+7,518	New	+$816K	0.49%	46

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Capital Planning Advisors's IBB Position: Q4 2019 in Review

Capital Planning Advisors sold out of iShares Biotechnology ETF (IBB) in Q4 2019, closing a stake of 360 shares — an estimated $36K sold.

Capital Planning Advisors first reported a position in IBB in Q4 2015 and held it in 10 quarters. The position peaked at $2.96M in Q4 2017. 710 funds tracked by Wall St. Rank hold IBB as of Q4 2019.

Capital Planning Advisors reported no remaining iShares Biotechnology ETF position as of Q4 2019 after selling out during the quarter.
Capital Planning Advisors sold 360 iShares Biotechnology ETF shares in Q4 2019, an estimated $36K.
Capital Planning Advisors first reported a position in iShares Biotechnology ETF in Q4 2015 and held it in 10 quarters.
Capital Planning Advisors's iShares Biotechnology ETF position peaked at $2.96M in Q4 2017.
710 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2019.

Based on Capital Planning Advisors's 13F filing for Q4 2019, filed 3 Feb 2020.